Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Ver gráficos interactivos y estados completos →
| Cuenta de resultados | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $0M | $0M | $9M | $2M | $1M | $0M | $0M | $0M | $0M |
| Beneficio bruto | ($206M) | $0M | ($144M) | ($84M) | ($1M) | ($2M) | ($1M) | ($1M) | $0M |
| % de margen bruto | — | — | -1682.0% | -3445.8% | -80.0% | — | — | — | — |
| Ingresos operativos (EBIT) | ($357M) | ($326M) | ($200M) | ($126M) | ($215M) | ($167M) | ($62M) | ($36M) | ($23M) |
| % de margen operativo | — | — | -2340.3% | -5164.4% | -14684.8% | — | — | — | — |
| Ingresos netos | ($327M) | ($303M) | ($183M) | ($123M) | ($213M) | ($167M) | ($62M) | ($36M) | ($27M) |
| % de margen neto | — | — | -2137.5% | -5037.9% | -14554.1% | — | — | — | — |
| EBITDA | ($326M) | ($303M) | ($182M) | ($123M) | ($215M) | ($167M) | ($62M) | ($35M) | ($26M) |
| Beneficio por acción (EPS) | $-13.83 | $-13.48 | $-10.21 | $-18.69 | $-69.33 | $-58.96 | $-24.23 | $-31.01 | $-29.99 |
| Acciones en circulación (M) | 29M | 23M | 18M | 7M | 3M | 3M | 3M | 1M | 1M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de PRAX. /companies/us/PRAX
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms